Skip to content

Acetyl-L-carnitine and mood: grade C

Limited evidence. Direction: Benefit.

Evidence maturity: Emerging

Why this grade

Rubric condition met: Meta-analyses exist but only in clinical populations (mostly diagnosed depressive and dysthymic disorders), extrapolated to healthy adults; pooled placebo comparison highly heterogeneous

Two meta-analyses (12 RCTs, 791 participants, nine pooled against placebo or no intervention; 15 studies, 809 participants) report fewer depressive symptoms than placebo, with high heterogeneity (I-squared 86%) in the 2018 analysis, and both call for larger trials. All populations were clinical, so the finding does not transfer to mood in healthy adults. A meta-analysis that mostly pools clinical populations does not count toward B for healthy adults, and clinical-only evidence caps the grade at C.

How sure are we?

Evidence maturity: Emerging Meta-analyses exist (12 RCTs, 791 participants; 15 studies, 809 participants), but no preregistered independent trial was confirmed; the population is diagnosed depressive disorders.

Tested as: Acetyl-L-carnitine

Who paid for the studies
Mostly independent
Risk of bias
Not assessed
Trial registry check
Not checked yet
Publication bias
None found. Funnel-plot results not reported in the abstracts read; B3 not assessed.
Outcome measured
A test score, rating scale or performance measure
Who was studied
Clinical populations only
Rules applied
Population cap (logged, no further change): Mostly diagnosed depressive disorders
  • Could rise: Would move to B for the clinical population if a preregistered, independent RCT were positive on its primary outcome. For healthy adults, any controlled trial is needed first.
  • Could fall: Would move to C none if a preregistered RCT of adequate size in diagnosed depression were null.

Science is provisional. This grade reflects the evidence we found as of . Next review: .

Maturity sits beside each grade. The grade says what the evidence shows; maturity says how much of it there is and how well it is confirmed.

Established
many trials from several independent teams, including at least one registered in advance
Emerging
two or more trials, or one large registered trial, not yet independently confirmed
Early signal
one trial, small pilots, or results only on secondary outcomes
Mechanistic only
lab, animal or biomarker data, or uncontrolled reports; no controlled human results
Traditional use only
a traditional-use monograph and nothing else

How we grade evidence

Studies this grade rests on

EffectMixedNo effectSize shows participants (n)20102015202020252030Meta-analysisRCTKumar 2026, 2026: meta-analysis, n = 809, result not recordedVeronese 2018, 2018: meta-analysis, n = 791, result not recordedBersani 2013, 2013: RCT, n = 80, result not recorded
each study this grade rests on, by publication year and design. Solid: effect versus the comparator; half-filled: mixed; hollow: no effect; dashed: result not recorded yet. Larger marks had more participants.
Show the numbers
StudyYearDesignParticipantsResult
Bersani 20132013RCT80result not recorded
Veronese 20182018meta-analysis791result not recorded
Kumar 20262026meta-analysis809result not recorded

L-Acetylcarnitine in dysthymic disorder in elderly patients: a double-blind, multicenter, controlled randomized study vs. fluoxetine.

Bersani G, Meco G, Denaro A. L-Acetylcarnitine in dysthymic disorder in elderly patients: a double-blind, multicenter, controlled randomized study vs. fluoxetine Eur Neuropsychopharmacol, 2013. PMID 23428336

Result not recorded
Design
7-week multicenter double-blind double-dummy randomized trial against an active antidepressant comparator (no placebo arm)
Sample
n = 80
Population
Older adults with diagnosed dysthymic disorder (clinical population)
Funding
not stated

Current Evidence of Acetyl-L-Carnitine Use in Mood Disorders-: A Systematic Review and Meta-Analysis.

Kumar R, Hashempour Z, Shahriarirad S. Current Evidence of Acetyl-L-Carnitine Use in Mood Disorders-: A Systematic Review and Meta-Analysis Neuropsychiatr Dis Treat, 2026. PMID 42261369

Result not recorded
Design
Systematic review (15 studies) and meta-analysis (10 studies); 14 RCTs and 1 open-label study
Sample
n = 809
Population
Adults with major depressive disorder or bipolar disorder (clinical populations)
Funding
not stated; author COI lists industry advisory roles and grants unrelated to acetyl-L-carnitine (see coi)

Acetyl-L-Carnitine Supplementation and the Treatment of Depressive Symptoms: A Systematic Review and Meta-Analysis.

Veronese N, Stubbs B, Solmi M. Acetyl-L-Carnitine Supplementation and the Treatment of Depressive Symptoms: A Systematic Review and Meta-Analysis Psychosom Med, 2018. PMID 29076953

Result not recorded
Design
Systematic review and meta-analysis of 12 RCTs
Sample
n = 791
Population
Adults with depressive symptoms, mostly clinical populations (mean age 54)
Funding
Department of Health ICA-CL-2017-03-001 (author grant listed in PubMed)

Search and history

Search (): (acetylcarnitine[ti] OR acetyl-L-carnitine[ti] OR "acetyl L carnitine"[ti]) AND (depress*[tiab] OR mood[tiab]) AND (meta-analysis[pt] OR systematic review[pt])

  • Graded C (awaiting approval)
  • C to C (awaiting approval) (maturity: emerging): Maturity, bias summary and re-check date added
  • C to C (approved) (maturity: emerging): Editor sign-off November 16, 2026: grade matches the editor-approved final page